RE:ValueWelcome Mbxwatcher.....Voyageur management has constantly over stated and under produced, thus one of the mean reasons IMO, we are sitting at .08 The future does hold promise of reaping substantial gains. Patience is the key on this one. We do have the best resource outside of China.
China is learning from the conflict in Ukraine as to what sanctions can be imposed upon them when the imminent conflict btwn the US and China ignites. China is currently buying up as much precious metals as it can get its hands on and dumping US bonds. There will be zero medical grade barium sulphate available when conflict breaks out. Thus Voyaguer will ensure a North American supply.
War does not have to break out for Voyageur to become profitable. We must break the current monopoly in the contrast market. Voyageur's own supply should ensure this. Brent has stated that he expects sales in 10 years of approx 200 million. If we can get half way there, that should place our SP a minimum $1. Now $1 may not seem like much, but it is a 1,200% return from current levels.
The fullerene potential could turn the company quickly into a $10 stock, but as Brent has stated, still in the R&D stage. I have attached the 11 Jan 2021 PEA PR for some reference.
PEA-News-Jan-11-2021-1.pdf (voyageurpharmaceuticals.ca)